The present invention provides novel pharmaceutical compositions and
methods of treatment that utilize or comprise tetrac and/or another
thyromimetic compound. The pharmaceutical compositions of the invention
are capable of suppressing TSH secretion without inhibiting the pituitary
specific monodeiodinase type II and while reducing or avoiding the
thyromimetic stimulation of peripheral tissues compared to equivalent
TSH-suppressive doses of L-thyroxine (T4). The pharmaceutical compositions
of the invention are particularly useful for treating patients suffering
from malignancy or abnormal growth of the thyroid and for preventing
growth of residual thyroid tissue post thyroidectomy.
